Numbers in line; launches in FY23 likely drivers APIs, custom pharmaceutical services, biosimilar and complex formulations. It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe Q3FY22 Results: Reported steady set of numbers despite Covid revenue vacuum this quarter, in line with our estimates....